Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2051-1426

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies ; volume:7 ; number:1 ; day:22 ; month:8 ; year:2019 ; pages:1-15 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (22.8.2019), 1-15, 12.2019

Creator: Naing, Aung
Infante, Jeffrey
Goel, Sanjay
Burris, Howard
Black, Chelsea
Marshall, Shannon
Achour, Ikbel
Barbee, Susannah
May, Rena
Morehouse, Chris
Pollizzi, Kristen
Song, Xuyang
Steele, Keith
Elgeioushi, Nairouz
Walcott, Farzana
Karakunnel, Joyson
LoRusso, Patricia
Weise, Amy
Eder, Joseph
Curti, Brendan
Oberst, Michael

Contributor: SpringerLink (Online service)

DOI: 10.1186/s40425-019-0665-2

URN: urn:nbn:de:101:1-2020010521585884999802

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:47 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Naing, Aung
Infante, Jeffrey
Goel, Sanjay
Burris, Howard
Black, Chelsea
Marshall, Shannon
Achour, Ikbel
Barbee, Susannah
May, Rena
Morehouse, Chris
Pollizzi, Kristen
Song, Xuyang
Steele, Keith
Elgeioushi, Nairouz
Walcott, Farzana
Karakunnel, Joyson
LoRusso, Patricia
Weise, Amy
Eder, Joseph
Curti, Brendan
Oberst, Michael
SpringerLink (Online service)

Other Objects (12)

Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells

GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

A bridging assay for detection and characterization of anti-drug antibodies to dostarlimab, a new anti-PD-1 therapeutic monoclonal antibody

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells

GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

A bridging assay for detection and characterization of anti-drug antibodies to dostarlimab, a new anti-PD-1 therapeutic monoclonal antibody

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells

GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

A bridging assay for detection and characterization of anti-drug antibodies to dostarlimab, a new anti-PD-1 therapeutic monoclonal antibody

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells

GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

A bridging assay for detection and characterization of anti-drug antibodies to dostarlimab, a new anti-PD-1 therapeutic monoclonal antibody

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells

GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

A bridging assay for detection and characterization of anti-drug antibodies to dostarlimab, a new anti-PD-1 therapeutic monoclonal antibody

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Highly efficient hybridoma generation and screening strategy for anti-PD-1 monoclonal antibody development

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells

GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy

Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)

A bridging assay for detection and characterization of anti-drug antibodies to dostarlimab, a new anti-PD-1 therapeutic monoclonal antibody

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Related objects

Reset password